Reported here is a new theranostic agent, 1, which consists of a Gd3+-texaphyrin core conjugated to a doxorubicin prodrug via a disulfide bond undergoing cleavage in the presence of glutathione, a species typically upregulated in cancer cells. To improve the solubility and tumor targeting of 1, it was loaded into folate receptor-targeted liposomes to produce FL-1. FL-1 was found to selectively produce a greater anti-proliferative effect in the case of the KB and CT26 cell lines as compared to the HepG2 and NIH3T3 cell lines. FL-1 was also found to provide enhanced MR imaging in vivo under conditions of T1 contrast in the early stage of metastatic cancer progression.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords